hydroxyurea has been researched along with Leukemia, Smoldering in 3 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "In polycythemia vera (PV), treatment with chlorambucil and radioactive phosphorus (p32) increases the risk of leukemic transformation from 1% to 13-14%." | 7.69 | Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. ( Fisher, SG; Godwin, J; Nand, S; Stock, W, 1996) |
| "In polycythemia vera (PV), treatment with chlorambucil and radioactive phosphorus (p32) increases the risk of leukemic transformation from 1% to 13-14%." | 3.69 | Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. ( Fisher, SG; Godwin, J; Nand, S; Stock, W, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (33.33) | 18.7374 |
| 1990's | 2 (66.67) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ohyashiki, K | 1 |
| Yokoyama, K | 1 |
| Kimura, Y | 1 |
| Ohyashiki, JH | 1 |
| Ito, T | 1 |
| Kuratsuji, T | 1 |
| Komatsumoto, S | 1 |
| Nara, M | 1 |
| Toyama, K | 1 |
| Nand, S | 1 |
| Stock, W | 1 |
| Godwin, J | 1 |
| Fisher, SG | 1 |
| De Gaetano, G | 1 |
| Sonnino, A | 1 |
3 other studies available for hydroxyurea and Leukemia, Smoldering
| Article | Year |
|---|---|
Myelodysplastic syndrome evolving into a myeloproliferative disorder: one disease or two?
Topics: Aged; Anemia, Macrocytic; Anemia, Refractory; Anemia, Refractory, with Excess of Blasts; Bone Marrow | 1993 |
Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
Topics: Acute Disease; Anemia, Refractory, with Excess of Blasts; Busulfan; Cell Transformation, Neoplastic; | 1996 |
[Long-time treatment with full-dosage ranitidine in a case of myelodyserythropoiesis (blastic leukosis) treated with prednisone and antiblastic agents].
Topics: Aged; Anemia, Refractory, with Excess of Blasts; Drug Evaluation; Humans; Hydroxyurea; Male; Mercapt | 1988 |